Vanda Pharmaceuticals Netherlands

Vanda tradipitant update: FDA re-review extends to Dec. 5, 2025

FDA · 6 min

Vanda Pharmaceuticals controversy now centers on tradipitant’s regulatory timeline and the next catalyst set. The FDA and Vanda agreed to extend the expedited re-review of the partial clinical hold to Dec. 5, 2025, while multiple tradipitant studies remain active or recruiting.